Clinical trial · Interventional
Barrett's Esophagus - 315 - 3 Way Cross-Over
A Multicenter, Double-blind, Three-way Crossover Intraesophageal and Intragastric pH Study of Three Esomeprazole Treatment Regimens in Documented Barrett's Esophagus Patients
NCT00637559CI-TRIAL-00004338completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study looks the intragastric and intraesophageal pH in patients with documented Barrett's esophagus whilst taking esomeprazole 40mg twice daily, esomeprazole 40mg three times daily, esomeprazole 20 mg three times daily.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Barrett's Esophagus | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Esomeprazole Magnesium | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- 1
- description
- 40mg twice daily
- interventionNames
- Drug: Esomeprazole Magnesium
- type
- EXPERIMENTAL
- label
- 2
- description
- 40mg three times daily
- interventionNames
- Drug: Esomeprazole Magnesium
- type
- EXPERIMENTAL
- label
- 3
- description
- 20mg three times daily
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Must have a previously established, biopsy-proven diagnosis of Barrett's esophagus with segment length greater than 3cm, with no dysplasia or adenocarcinoma within the previous 12 months Exclusion Criteria: * A history of esophageal, gastric, or duodenal surgery, including anti-reflux surgery or endoscopic anti-reflux procedures, except for simple closure of a gastric or duodenal ulcer. * History of various gastrointestinal diseases - please see investigator for full list. * Evidence of any malignant disease in the last 5 years, except minor superficial skin disease. * Unstable diabetes mellitus. Stable on a controlled diet, oral agents or insulin are acceptable.
References
Publications (0)
Data not yet available
No reference posted for this study.